PharmaCyte Biotech Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly20.2MTarget: Maintain sufficient runway to resolve FDA clinical hold
Revenue Quarterly0.0Target: 0 (Pre-revenue clinical-stage)
Operating Loss Quarterly-15MTarget: Minimize non-R&D overhead burn
Watch Items
- FDA Clinical Hold on LAPC INDTrigger: FDA formal response or lifting of the holdAction: Re-evaluate clinical trial timeline and protocol design for CypCaps
- Strategic Investments and Asset MonetizationTrigger: Material changes in stakes of external biotech companies (e.g., QCLS, TNF Pharmaceuticals)Action: Assess capital allocation efficiency and impact on cash runway
- Reverse Stock Split ImplementationTrigger: Board decision to execute split within the approved 1-for-1.1 to 1-for-100 rangeAction: Monitor stock price compliance with Nasdaq minimum bid price requirements
Research as of 20 Jun 2026